#None #Barcelona #OncoHost #Lung Cancer #WCLC2025

OncoHost's Groundbreaking Findings on Small Cell Lung Cancer At WCLC 2025

OncoHost, a pioneering technology company that significantly reshapes precision medicine, recently announced that its research has been accepted for a poster presentation at the prestigious International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, scheduled for September 6-9 in Barcelona, Spain.

The research titled "Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis" reveals the innovative approach that OncoHost is taking to enhance precision medicine for small cell lung cancer (SCLC). The study sheds light on how the analysis of plasma proteomics can lead to the identification of unique subtypes of SCLC, providing crucial insights that could influence treatment decisions and patient outcomes.

Key Findings of the Study

The study underscores that SCLC is a heterogeneous disease, meaning that it consists of various subtypes, each exhibiting distinct clinical characteristics. This complexity implies different mechanisms of therapeutic resistance that make designing effective treatments particularly challenging. To approach this issue, the researchers explored the use of molecular subtyping based on specific markers in tumor samples. The results suggest that these subtypes possess unique biological features and gene expression patterns, which could potentially lead to targeted therapies.

Despite the promise of molecular subtyping, the current methodologies face two significant limitations. The heterogeneity present in tumors can lead to inconsistent test results across various biopsy sites. Moreover, research indicates the possibility that tumor subtypes may change during treatment, a phenomenon that highlights the plasticity of tumors and their adaptation to therapeutic pressures.

Considering these challenges, the OncoHost research team adopted a non-invasive strategy by examining pre-treatment plasma samples from 79 patients diagnosed with extensive-stage SCLC who were treated with either immune checkpoint inhibitors or chemotherapy. The analysis revealed five distinct proteomic subtypes characterized by specific molecular features and clinical responses. Notably, these subtypes demonstrated varying survival rates in relation to the ICI-based treatment they received.

Proteomic Insights and Future Directions

Through their comprehensive proteomic profiling, the team identified 469 differentially expressed proteins across the various patient subtypes. These proteins clustered into four major expression pathways, which were significantly associated with cell cycle regulation, inflammation, splicing, and other critical biological processes. The research also highlighted differences in neuroendocrine and NOTCH signaling pathways, which are known to be critical in the progression of SCLC and its treatment responses.

The implications of these findings are noteworthy as they suggest that plasma proteomics-based subtyping could serve as a pivotal non-invasive method to monitor disease progression and offer dynamic treatment insights. This approach opens new avenues for identifying therapeutic targets and advancing personalized treatment strategies in the management of SCLC, potentially improving patient outcomes significantly.

Comments from OncoHost Leaders

Dr. Michal Harel, Vice President of Translational Medicine at OncoHost, stated, "Small cell lung cancer remains one of the most challenging malignancies to treat due to its complexity and poor prognosis. Our findings indicate that plasma proteomics can reveal clinically significant SCLC subtypes, uncovering novel biological pathways that could become future therapeutic targets."

Dr. Ofer Sharon, CEO of OncoHost, also commented, "By marrying proteomic profiling with artificial intelligence capabilities in the context of SCLC, we are extracting actionable insights that could revolutionize treatment decision-making. This research underscores our commitment to providing oncologists with predictive tools aimed at enhancing patient outcomes in the face of aggressive cancers."

About OncoHost

OncoHost is at the forefront of transforming precision medicine to foster better patient outcomes, operating out of Binyamina, Israel, and Cary, North Carolina. The company's unique platform, PROphet®, utilizes a plasma-based proteomic pattern analysis to guide immunotherapy decisions in non-small cell lung cancer (NSCLC) based on a single blood sample. This test has been clinically validated, demonstrating significant effectiveness in counseling healthcare providers regarding optimal first-line immunotherapy tailored to individual patients.

Having attracted widespread attention, OncoHost is positioned to spearhead advancements in precision diagnostics and biomarker development, supported by an extensive clinical trial network that includes over 40 sites and 1,700 patients globally. For further information, visit www.oncohost.com and follow OncoHost on social media platforms for the latest updates.